"PHYRAGO™ represents a novel dasatinib formulation that delivers equivalent efficacy to ... PHYRAGO™ allows concomitant use with a proton pump inhibitor or H2 receptor antagonist." ...

Use of proton pump inhibitors appears to increase the risk for kidney failure among patients with CKD. Use of proton pump inhibitors (PPIs) may spur progression to kidney failure in patients with ...

A growing body of evidence links use of proton pump inhibitors to kidney problems, including kidney failure in patients with existing CKD.

Proton-pump inhibitors (PPIs) are the most effective medical therapy for patients with moderate-to-severe GERD and are widely prescribed to pregnant women. However, safety data about the use of ...

Objective To determine whether new users of proton pump inhibitors (PPIs) are at an increased risk of gastric cancer compared with new users of histamine-2 receptor antagonists (H2RAs). Design Using ...

1 Department of Gastroenterology and Hepatology, West China Hospital, Sichuan University, Chengdu, China 2 Department of Geriatrics and National Clinical Research Center for Geriatrics, West China ...

Expert Rev Clin Pharmacol. 2013;6(4):443-451.

Unconventional Computing Laboratory, University of the West of England, Bristol BS16 1QY, U.K.

Objectives This study aimed to assess whether the combined use of proton pump inhibitors (PPIs) with non-steroidal anti-inflammatory drugs (NSAIDs) or antibiotics (penicillins, macrolides, ...